更新于：2024-11-21

Trinitrate

三硝酸酯

更新于：2024-11-21

概要

概要

基本信息

简介三硝酸酯是默克公司研制的一种小分子药物，于 1983 年首次进入医药市场。该药物具有双重属性：它可作为可溶性鸟苷酸环化酶 (sGC) 的催化剂，以及一氧化氮供体。硝酸甘油的适用范围广泛，包括心绞痛、勃起功能障碍、疼痛和肛裂。通过激发 sGC 刺激和释放一氧化氮，这种多用途药物会导致血管舒张，最终缓解上述疾病。

药物类型

小分子化药

别名

1,2,3-propanetrioltrinitrate、1,2,3-propanetriyl nitrate、Anrecta

+ [41]

靶点

ALDH2

作用机制

ALDH2刺激剂(乙醛脱氢酶刺激剂)、一氧化氮供体

治疗领域

免疫系统疾病神经系统疾病心血管疾病+ [3]

在研适应症

勃起功能障碍肛裂疼痛+ [3]

非在研适应症

冠心病心脏衰竭

原研机构

Merck & Co., Inc.

在研机构

Sun Pharma Japan Ltd.Evus Health Solutions LLC

Futura Medical Plc

+ [8]

非在研机构

Futura Medical Developments Ltd.

山东步长制药股份有限公司Forest Laboratories, Inc.

+ [2]

最高研发阶段批准上市

首次获批日期

日本 (1979-04-13),

心绞痛心源性哮喘心肌梗塞

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

结构

分子式C3H5N3O9

InChIKeySNIOPGDIGTZGOP-UHFFFAOYSA-N

CAS号55-63-0

关联

294

项与三硝酸酯相关的临床试验

NCT06682260 / Not yet recruiting临床4期IIT

Impact of Nitroglycerin-induced Vasodilation on Stroke Volume and Diuretic Response in Acute Heart Failure: a Protocol for a Mechanistic Trial

This study aims to understand how nitroglycerin affects patients with acute heart failure, a condition where the heart struggles to pump blood effectively, leading to fluid buildup and breathing difficulties. Nitroglycerin relaxes blood vessels to ease the heart's workload and may help reduce fluid buildup. The investigators hypothesize that nitroglycerin can increase blood flow from the heart and promote urine production, which may reduce congestion in AHF patients. By studying heart function, blood volume, and fluid levels during treatment, the goal is to identify which patients may benefit most from nitroglycerin therapy.

开始日期2025-01-01

申办/合作机构

Copenhagen University Hospital

TCTR20240923005 / Not yet recruiting临床4期IIT

Feasibility of high-dose intravenous nitroglycerin in sympathetic crash acute pulmonary edema (SCAPE) in the emergency department of Siriraj Hospital

开始日期2024-09-30

申办/合作机构-

CTRI/2024/09/074462 / Not yet recruitingN/AIIT

Comparison of low dose vs high dose nitroglycerine in management of acute pulmonary edema for the reduction of mean arterial pressure. - nil

开始日期2024-09-30

申办/合作机构-

100 项与三硝酸酯相关的临床结果

登录后查看更多信息

100 项与三硝酸酯相关的转化医学

登录后查看更多信息

100 项与三硝酸酯相关的专利（医药）

登录后查看更多信息

14,369

项与三硝酸酯相关的文献（医药）

2025-02-01·International Journal of Obstetric Anesthesia

Anaesthetic considerations for impacted fetal head at caesarean delivery: a focused review

Review

作者: Ragbourne, S C ; Desai, N ; Ragbourne, S.C. ; Charles, E. ; Charles, E ; Herincs, M ; Desai, N. ; Herincs, M.

BACKGROUNDImpacted fetal head occurs when the fetal head is deeply engaged within the maternal pelvis and difficult to deliver during caesarean delivery. In order to deliver the fetal head, additional surgical manoeuvres and/or pharmacological tocolysis are needed. The aim of this focused review is to outline the incidence, risk factors, management and complications of this obstetric emergency from the perspective of the anaesthetist.METHODSDatabases were searched for free text headings and subject headings associated with different permutations of terms related to impacted fetal head and caesarean delivery.RESULTSImpacted fetal head has been estimated to occur in 1.5 % of elective caesarean deliveries and 2.9-18.4% of all emergency caesarean deliveries at any cervical dilatation. Risk factors include advanced cervical dilatation, labour augmentation with oxytocin, prolonged second stage of labour, fetal malposition and junior grade of operating obstetrician. If impacted fetal head occurs, the anaesthetist in conjunction with the multidisciplinary team should consider decreasing the height of the operating table, providing a step for the obstetrician to stand on, placing the patient in the head down position, providing pharmacological tocolysis with glyceryl trinitrate (or nitroglycerin), beta-2 adrenoreceptor agonists or volatile anaesthetic agents, and managing complications such as postpartum haemorrhage.CONCLUSIONImpacted fetal head is an obstetric emergency that the anaesthetist should be familiar with and has a vital role in managing. We propose an algorithm for management that may serve as a clinical decision aid.

2025-01-01·International Journal of Cardiology

Coronary CT angiography instead of invasive angiography before TAVI: Feasibility and outcomes

Article

作者: Parner, Erik ; Terkelsen, Christian Juhl ; Pedersen, Kamilla Bech ; Nørgaard, Bjarne Linde ; Mathiassen, Ole Norling ; Leipsic, Jonathon ; Jensen, Rebekka Vibjerg ; Grove, Erik Lerkevang ; Jensen, Jesper Møller ; Iraqi, Nadia

AIMSConcomitant coronary artery disease (CAD) is frequent in transcatheter aortic valve implantation (TAVI) candidates. Despite societal recommendations of performing invasive coronary angiography (ICA) for coronary assessment in the pre-TAVI diagnostic workup, the prognostic value of ICA and beneficial effect of revascularization in these patients remains unclear. We aimed to determine feasibility and outcomes following a strategy of cardiac CT + coronary CT angiography (cCTA) rather than cardiac CT + ICA before TAVI.METHODS AND RESULTSWe performed a single-center, observational cohort study including all patients, without previous coronary intervention, referred to TAVI between April 2020 and November 2021. CAD was assessed by cCTA, and only patients with proximal stenosis >70 %, or left main stenosis >50 %, or cCTA was non-evaluable regarding proximal segments were subsequently referred to ICA. 240 patients were included in the study. No adverse effects to pre-cCTA-scan nitroglycerin administration were observed. On cCTA, 92 % of the patients had atheroscerosis. 191 (80 %) patients had cCTA only performed, while 49 (20 %) patients underwent subsequent ICA. During a median (range) follow-up of 15 (6-25) months, no difference in procedural complication rates, mortality rates, or number of unplanned ICA was observed between patients evaluated with only cCTA vs cCTA+ICA.CONCLUSIONSUpfront cCTA instead of ICA for assessment of obstructive CAD in the diagnostic workup of patients with severe aortic stenosis referred to TAVI is feasible, safe, and with similar procedural and clinical outcomes. Randomized studies are warranted to further validate the safety of using CTA rather than ICA for coronary assessment in TAVI candidates.

2025-01-01·International Journal of Cardiology

Effects of radial artery spasm prophylaxis on intracoronary vasomotor responses during acetylcholine spasm provocation testing

Article

作者: Hubert, Astrid ; Schulte Steinberg, Benedict ; Bekeredjian, Raffi ; Ong, Peter ; Schäufele, Tim ; Nobre Menezes, Miguel ; Arndt, Helene ; Menezes, Miguel Nobre ; Sechtem, Udo ; Steinberg, Benedict Schulte ; Pereyra, Valeria Martínez ; Martínez Pereyra, Valeria

BACKGROUNDInvasive coronary angiography via the radial approach is commonly performed following radial artery spasm prophylaxis (RASP). It is however unknown, whether RASP influences the results of coronary spasm provocation testing performed after diagnostic angiography. We aimed to investigate the effects of RASP on vasomotor responses during intracoronary acetylcholine (ACh) testing.METHODSWe retrospectively screened 372 consecutive patients (51 % female, mean age 61 ± 11 years) with angina and non-obstructive coronary arteries, who underwent intracoronary provocation with ACh according to a standardized protocol. During testing, dose-dependent clinical discomfort and concomitant ischemic electrocardiographic changes were recorded in addition to visual reductions of epicardial lumen diameters. Of these patients, 156 (42 %) received RASP (i.e. 200 μg nitroglycerin and 2.5 mg verapamil), while no RASP was administered in 216 (58 %) patients. Both groups were compared regarding age, sex, cardiovascular risk factors and ACh-test results.RESULTSACh provocation testing revealed a pathological test result in 71 patients (46 %) with RASP and 103 patients (48 %) without (p = 0.752) [epicardial spasm: in 20 patients (28 %) with RASP and 42 patients (41 %) without (p = 0.120); microvascular spasm: in 51 patients (72 %) with RASP and 61 patients (59 %) without (p = 0.362)]. Overall, RASP did not significantly alter coronary artery vasomotor responses, neither regarding the frequency (p = 0.752) or type of coronary spasm (microvascular vs. epicardial; p = 0.108) nor regarding the ACh dose leading to spasm (p = 0.151).CONCLUSIONSRASP does not significantly affect coronary vasomotor responses to ACh, suggesting that radial artery spasm prophylaxis can be routinely administered even in patients in whom intracoronary spasm testing is performed.

项与三硝酸酯相关的新闻（医药）

2024-11-18

·医药云端工作室

三明联盟“六病共管”集采，19个药品+3个耗材，可复活！七氟烷有专门规定（附名单）

编辑：子非鱼 11月18日，三明联盟牵头开展的肿瘤和呼吸等疾病药耗集采终于浮出水面，该集采征求意见稿公布，意见征求期限截至2024年11月22日。19个品种纳入集采，采购周期为2年，有复活规则。值得注意的是，广受行业关注的七氟烷新旧批文问题，方案显示：存在新旧批文的七氟烷申报企业，约定采购量可统一合并至新批文处理。本次集采方案包括药品和耗材两个采购文件，药品分为目录一（14个品种）和目录二（5个品种），其中硝酸甘油按过评、未过评分列二个目录中，其实应该19个品种。而耗材部分采购品种为一次性使用气管插管（包含不限于国家医保局医保医用耗材编码为 C142501209）、一次性活体取样钳/活检钳（包含不限于国家医保局医保医用耗材编码为 C010226007）、以及一次性使用热活检钳（包含不限于国家医保局医保医用耗材编码 C010227007）。药品部分采购周期为两年。根据申报品种的相关资质及约定采购量占比区分为 A、B 两组，分别竞价；福尔可定不分组。原研、参比制剂、过评品种，以及新3、新4类批件，可在《化学药品目录集》中查询到相应结果的为 A 组，其余为 B 组。同通用名下无过评药品约定采购量累计达前 80%的企业列入 A 组，其余为 B 组。拟中选规则 1.申报企业≤3 家的组别，中选企业为 1 家，申报价格从低到高排名第 1 且符合以下条件之一的为拟中选企业：（1）报价降幅达到所有组别的平均降幅；（2）报价降幅达 20%。 2.申报企业＞3 家的组别，中选企业为 2 家，申报价格从低到高排名第 1、第 2 的为拟中选企业，其中次低价企业报价不高于最低价企业的 1.3 倍。 3.纠偏规则如 B 组报价高于 A 组最低拟中选价格，B 组拟中选产品需将报价调整至不超过 A 组最低拟中选价格的 70%，如愿意接受纠偏则拟中选，如不愿意，则该组流标。 4.复活规则如未中选企业约定采购量在同通用名品种中排名第一，愿下调价格，降幅达到至（目录一）中选产品平均降幅的 50%，获得复活资格，排名在其余拟中选企业之后。（三）当出现企业报价相同情况时，排名按以下规则依次确定： 1.约定采购量大的企业优先； 2.首次获得国内药品注册批件时间在前的产品优先。目录二品种拟中选企业确定（一）申报企业在各省级、省际联盟集采曾中选的，不高于其历次最低中选价格，确定为拟中选企业。（二）申报企业在各省级、省际联盟集采未曾中选的，不高于通用名产品最低中选价格，确定为拟中选企业。（三）当出现报价相同情况时，排名按以下规则依次确定： 1.约定采购量大的企业优先； 2.首次获得国内药品注册批件时间在前的产品优先。（四）申报品种区分过评与非过评，按各质量层次集采中选情况进行价格联动，如此次非过评产品报价高于过评产品最低拟中选价格，则非过评产品不予入选。存在新旧批文的七氟烷申报企业，约定采购量可统一合并至新批文处理。约定采购量分配（一）目录一品种 1.申报企业≤3 家的组别：（1）该组无复活企业，中选企业获得该组需求量的 80%作为约定采购量。（2）该组有复活企业，复活企业获得医疗机构上报该企业需求量的 30%作为约定采购量，该组剩余需求量分配给排名第一的中选企业。 2.申报企业＞3 家的组别：（1）该组无复活企业，中选企业获得该组需求量的 100%作为约定采购量，其中排名第一的中选企业不少于该组约定采购量的 50%，其余由医疗机构在中选企业中自主分配。（2）该组有复活企业，复活企业获得医疗机构上报该企业需求量的 30%作为约定采购量，该组剩余需求量由医疗机构在中选企业中分配，其中排名第一的中选企业不少于剩余量的 50%。 3.如某一组流标（无中选及复活企业），则该组需求量的50%分配给另一组。（二）目录二品种 1.确定基础量：中选企业获得医疗机构对其所报需求量的70%作为基础量。 2.确定增量：申报企业报价与其最低中选价格（未曾中选企业以通用名产品历史最低中选价格为基准）相比，降幅每增加1%相应增加医疗机构对其所报需求量 1.5%（最多不超过 30%）。 3.分配剩余量：中选企业需求量扣除基础量和增量部分以及未中选企业需求量作为剩余量，分配给最低价中选企业。三明联盟集采：从呼吸、抗肿瘤用药到“六病共管”用药及耗材 5月20日，国家医保局发出《国家医疗保障局办公室关于加强区域协同做好2024年医药集中采购提质扩面的通知》(医保办发(2024) 8号 )，明确点名三明联盟牵头进行呼吸、抗肿瘤药物集采。而三明联盟和上海瑞金医院合作的“六病共管”已有一定的基础，从“两病”顺势扩展到“六病”，也并非不可能，反而在已有经验基础上有更大的扩展空间。事实上，9月下旬业内流传的集采征求意见稿显示的20个药品，也并不局限在呼吸、抗肿瘤领域。基于此，之前我们在解读三明联盟集采时也据此猜测下一步该联盟集采并不排除将相关耗材纳入其中，这样，从药品集采到“按病种集采”的逻辑才能自洽。当然，通知只是要求医疗机构报量，最终是否纳入集采还需要进一步观察。随着9月下旬黑龙江全省13个地市的全部加入，目前三明联盟成员已包括18省53个地级市、4个医改示范县，覆盖区域人口接近1.9亿，是一个不可小觑的采购联盟。此前关于三明联盟集采的分析文章，可点击：三明联盟“六病共管”集采，江西报量，删除4个药品（附名单）三明联盟“六病共管”集采，开始报量，药品删除2个，耗材删1个品种三明联盟正式发文，21个品种，新增七氟烷！三明新动向！联盟扩容，做好“六病”用药、耗材集采三明联盟集采，纳入20个品种“六病共管”，5点解读，2点猜测 “六病共管”用药集采，三明联盟即将登场！4点猜测...... 关注公众号，获取可靠、专业的资讯和分析内容

带量采购

2024-11-04

·drugs

VitalityVita Issues Voluntary Nationwide Recall of VitalityXtra and PeakMax Capsules Due to the Presence of Undeclared Sildenafil and Diclofenac

Audience: Consumers November 4, 2024 – Sacramento, CA, VitalityVita.com is voluntarily recalling lot 230811, Exp 8/11/25 , of VitalityXtra Capsules and PeakMax Capsules packaged in 10-count blisters in a cardboard carton to the consumer level. VitalityXtra was found to be tainted with sildenafil, an ingredient in FDA approved products for treatment of male erectile dysfunction in the family of drugs known as phosphodiesterase (PDE-5) inhibitors. PeakMax capsules was found to be tainted with sildenafil and diclofenac, an FDA approved drug known as a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. Products containing sildenafil and diclofenac cannot be marketed as dietary supplements. VitalityVita and PeakMax capsules are unapproved new drugs for which safety and efficacy have not been established and, therefore, subject to recall. Consumption of products with undeclared sildenafil may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may cause a significant drop in blood pressure that may be life threatening. People with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. Among the adult male population, who are most likely to use this product, adult males who use nitrates for cardiac conditions are most at risk. Use of products with undeclared diclofenac may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines. This hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products. To date, VitalityVita has not received any reports of adverse events related to this recall. The products were distributed via the internet at VitalityVita.com nationwide in the USA. VitalityXtra and PeakMax are marketed as dietary supplements for male performance and energy and are packaged in 10-count blisters packaged in an (VitalityXtra -Green, Yellow White Carton) and (PeakMax in Purple, Yellow and White carton) Lot#: 230811 Exp 8/11/25. The product can be identified by the labels below. VitalityVita is notifying its distributors and customers by this press announcement and is arranging for return of all recalled products. Please send all returns to 2108 N ST #7929 Sacramento, CA 95816. Consumers that have VitalityXtra or PeakMax capsules lot number 230811 should stop using the product. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product. Consumers with questions regarding this recall can contact VitalityVita via e-mail at vitalityvitacorp@gmail.com Monday through Friday 9AM – 5PM PST. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. Source: FDA Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2024-11-03

·信狐药迅

科伦博泰ADC新药芦康沙妥珠第三项适应症非小细胞肺癌提交上市申请|新受理（10.28-11.3）

本周药品注册受理数据，分门别类呈现，一目了然。(10.28-11.3）新药上市申请药品名称企业注册分类受理号马来酸噻吗洛尔凝胶上海奥全生物医药科技有限公司2.4CXHS2400111注射用芦康沙妥珠单抗四川科伦博泰生物医药股份有限公司1CXSS2400117 新药临床申请药品名称企业注册分类受理号SYHX1901片石药集团欧意药业有限公司1CXHL2401160SYHX1901片石药集团欧意药业有限公司1CXHL2401158SYHA1813口服溶液上海润石医药科技有限公司1CXHL2401166SYHA1813口服溶液上海润石医药科技有限公司1CXHL2401165SYHA1813口服溶液上海润石医药科技有限公司1CXHL2401164注射用MB0151主流源生物科技(上海)有限公司1CXHL2401162苯磺酸CG-0255胶囊上海柯君医药科技有限公司1CXHL2401153苯磺酸CG-0255胶囊上海柯君医药科技有限公司1CXHL2401152HY-072808软膏合肥恩瑞特药业有限公司1CXHL2401156HY-072808软膏合肥恩瑞特药业有限公司1CXHL2401155HRN01片北京华睿鼎信科技有限公司1CXHL2401144HRN01片北京华睿鼎信科技有限公司1CXHL2401143XY0507注射液南京相元生物医药科技有限公司1CXHL24011391D228片广州中科莱恩药物研究有限公司1CXHL2401138伊匹乌肽雾化吸入溶液益承康泰(厦门)生物科技有限公司1CXHL2401136SYH2051片石药集团中奇制药技术(石家庄)有限公司1CXHL2401135SYH2051片石药集团中奇制药技术(石家庄)有限公司1CXHL2401134盐酸(R)-氯胺酮注射液江苏豪森药业集团有限公司2.1CXHL2401161盐酸(R)-氯胺酮注射液江苏豪森药业集团有限公司2.1CXHL2401159BN020827H山东百诺医药股份有限公司2.2CXHL2401157HQ2216注射液百诚医药(珠海横琴)有限公司2.2CXHL2401154HB018口溶膜合肥华方医药科技有限公司2.2CXHL2401151HB018口溶膜合肥华方医药科技有限公司2.2CXHL2401150HB018口溶膜合肥华方医药科技有限公司2.2CXHL2401149司美格鲁肽注射液中山万汉制药有限公司2.2CXHL2401148司美格鲁肽注射液中山万汉制药有限公司2.2CXHL2401147HXASP028广西善合百升科技有限公司2.2CXHL2401146HXASP028广西善合百升科技有限公司2.2CXHL2401145硫酸阿托品滴眼液山东威智百科药业有限公司2.2CXHL2401142CB275舌下膜杭州成邦医药科技有限公司2.2CXHL2401141CB275舌下膜杭州成邦医药科技有限公司2.2CXHL2401140HQ2303百诚医药(珠海横琴)有限公司2.3CXHL2401163SMF-213江西施美药业股份有限公司2.3CXHL2401137注射用HLX43上海复宏汉霖生物技术股份有限公司1CXSL2400747SYS6041石药集团巨石生物制药有限公司1CXSL2400746PJ008注射液重庆派金生物科技有限公司1CXSL2400745HM2002注射液上海环码生物医药有限公司1CXSL2400740BAT1308注射液百奥泰生物制药股份有限公司1CXSL2400739注射用BAT8007百奥泰生物制药股份有限公司1CXSL2400738RC148注射液荣昌生物制药(烟台)股份有限公司1CXSL2400737OCUL101注射液深圳欧科健生物医药科技有限公司1CXSL2400744OCUL101注射液深圳欧科健生物医药科技有限公司1CXSL2400743OCUL101注射液深圳欧科健生物医药科技有限公司1CXSL2400742注射用ALK201上海安领科生物医药有限公司1CXSL2400734SYS6045石药集团巨石生物制药有限公司1CXSL2400733恩朗苏拜单抗注射液石药集团巨石生物制药有限公司2.2CXSL2400741 仿制药申请药品名称企业注册分类受理号间苯三酚口崩片南京海纳制药有限公司3CYHS2403744恩格列净二甲双胍缓释片南京易亨制药有限公司3CYHS2403743多索茶碱片浙江花园药业有限公司3CYHS2403742多索茶碱片浙江花园药业有限公司3CYHS2403741盐酸甲氧氯普胺注射液平光制药股份有限公司3CYHS2403734盐酸溴己新口服溶液江苏开元药业有限公司3CYHS2403730盐酸纳美芬注射液甘肃农垦药物碱厂有限公司3CYHS2403723劳拉西泮片北京益民药业有限公司3CYHS2403722黄体酮注射液重庆万霖生物医药科技有限公司3CYHS2403721艾司奥美拉唑镁肠溶胶囊寿光富康制药有限公司3CYHS2403718艾司奥美拉唑镁肠溶胶囊寿光富康制药有限公司3CYHS2403717艾司奥美拉唑镁肠溶干混悬剂山东达因海洋生物制药股份有限公司3CYHS2403716盐酸纳美芬注射液舒美奇成都生物科技有限公司3CYHS2403715拉米夫定替诺福韦片石家庄龙泽制药股份有限公司3CYHS2403711重酒石酸去甲肾上腺素注射液江西人可医药科技有限公司3CYHS2403710重酒石酸去甲肾上腺素注射液江西人可医药科技有限公司3CYHS2403709托吡酯口服溶液海南斯达制药有限公司3CYHS2403708复方葡萄糖/电解质颅脑手术冲洗液昆明南疆制药有限公司3CYHS2403702钠钾镁钙注射用浓溶液河南上恒医药科技有限公司3CYHS2403726己酮可可碱缓释片广州仁恒医药科技股份有限公司3CYHS2403696磷酸奥司他韦干混悬剂广州白云山医药集团股份有限公司白云山制药总厂3CYHS2403695磷酸奥司他韦干混悬剂广州白云山医药集团股份有限公司白云山制药总厂3CYHS2403694磷酸奥司他韦干混悬剂山东百诺医药股份有限公司3CYHS2403691硝酸甘油注射液海南未见药业有限公司3CYHS2403689盐酸溴己新注射液中玉制药(海口)有限公司3CYHS2403688多索茶碱片重庆士立德医药科技有限公司3CYHS2403684多索茶碱片重庆士立德医药科技有限公司3CYHS2403683复方聚乙二醇电解质散(儿童型)重庆药谷制药有限公司3CYHS2403697琥珀酸美托洛尔缓释胶囊上海惠永制药有限公司3CYHS2403679醋酸钙口服溶液合肥恩瑞特药业有限公司3CYHS2403678奥贝胆酸片泰州复旦张江药业有限公司3CYHS2403677奥贝胆酸片泰州复旦张江药业有限公司3CYHS2403676复合磷酸氢钾注射液广东迈德珐医药科技有限公司3CYHS2403682硝普钠注射液山东齐都药业有限公司3CYHS2403660西吡氯铵含片广东万泰科创药业有限公司3CYHS2403659小儿复方氨基酸注射液(19AA-I)湖北长联杜勒制药有限公司3CYHS2403657盐酸甲氧氯普胺注射液河南利恒医药科技有限公司3CYHS2403665乳酸钠林格冲洗液石家庄四药有限公司3CYHS2403652己酮可可碱注射液国药集团容生制药有限公司3CYHS2403651盐酸阿莫罗芬乳膏苏州高迈药业有限公司4CYHS2403740熊去氧胆酸口服混悬液安士制药(中山)有限公司4CYHS2403739熊去氧胆酸口服混悬液安士制药(中山)有限公司4CYHS2403738沙库巴曲缬沙坦钠片常州四药制药有限公司4CYHS2403736沙库巴曲缬沙坦钠片常州四药制药有限公司4CYHS2403735依折麦布阿托伐他汀钙片湖北民康药业集团有限公司4CYHS2403733依折麦布阿托伐他汀钙片湖北民康药业集团有限公司4CYHS2403732地夸磷索钠滴眼液广东南国药业有限公司4CYHS2403731利格列汀二甲双胍片(II)安徽佳和药业有限公司4CYHS2403729门冬氨酸钾镁注射液湖南赛隆药业(长沙)有限公司4CYHS2403737丙戊酸钠口服溶液湖南省湘中制药有限公司4CYHS2403701枸橼酸钠血滤置换液宁波泰瑞斯科技有限公司4CYHS2403725替米沙坦氨氯地平片长春海悦药业股份有限公司4CYHS2403720替米沙坦氨氯地平片(II)北京百奥药业有限责任公司4CYHS2403719丙酸氟替卡松乳膏河北新张药股份有限公司4CYHS2403714富马酸伏诺拉生片山东诺明康药物研究院有限公司4CYHS2403713富马酸伏诺拉生片山东诺明康药物研究院有限公司4CYHS2403712二甲硅油乳剂南京海纳制药有限公司4CYHS2403707注射用氨苄西林钠舒巴坦钠圣嘉(滨海)生物医药科技有限公司4CYHS2403706注射用氨苄西林钠舒巴坦钠圣嘉(滨海)生物医药科技有限公司4CYHS2403705注射用氨苄西林钠舒巴坦钠圣嘉(滨海)生物医药科技有限公司4CYHS2403704左氧氟沙星滴眼液润尔眼科药物(广州)有限公司4CYHS2403700磷酸西格列汀片湖南迪诺制药股份有限公司4CYHS2403699吸入用乙酰半胱氨酸溶液远大医药(中国)有限公司4CYHS2403698阿法骨化醇软胶囊人福普克药业(武汉)有限公司4CYHS2403728阿法骨化醇软胶囊人福普克药业(武汉)有限公司4CYHS2403727门冬氨酸钾镁注射液山东齐都药业有限公司4CYHS2403703富马酸福莫特罗吸入溶液南京思聆医药科技有限公司4CYHS2403690注射用氯诺昔康江西科为制药有限公司4CYHS2403687头孢托仑匹酯颗粒海南葫芦娃药业集团股份有限公司4CYHS2403686米库氯铵注射液舒美奇成都生物科技有限公司4CYHS2403685富马酸伏诺拉生片安徽宏业药业有限公司4CYHS2403693富马酸伏诺拉生片安徽宏业药业有限公司4CYHS2403692地夸磷索钠滴眼液江苏广承药业有限公司4CYHS2403680卡前列素氨丁三醇注射液(预充式)湖州亚瑟制药有限公司4CYHS2403675卡维地洛片重庆士立德医药科技有限公司4CYHS2403674非奈利酮片山东朗诺制药有限公司4CYHS2403673非奈利酮片山东朗诺制药有限公司4CYHS2403672维生素B12滴眼液浙江莎普爱思药业股份有限公司4CYHS2403671布洛芬缓释胶囊国大(吉林)制药集团有限公司4CYHS2403670非布司他片辽宁新高制药有限公司4CYHS2403669布瑞哌唑片昆山龙灯瑞迪制药有限公司4CYHS2403668注射用盐酸美法仑兆科(广州)肿瘤药物有限公司4CYHS2403667洛索洛芬钠凝胶贴膏广东恒健制药有限公司4CYHS2403666复方托吡卡胺滴眼液深圳市瑞霖医药有限公司4CYHS2403681培哚普利氨氯地平片(III)浙江美迪深生物医药有限公司4CYHS2403664培哚普利氨氯地平片(I)浙江美迪深生物医药有限公司4CYHS2403663妥洛特罗贴剂北京泰德制药股份有限公司4CYHS2403662妥洛特罗贴剂北京泰德制药股份有限公司4CYHS2403661达格列净片石家庄市华新药业有限责任公司4CYHS2403658艾拉莫德片长春海悦药业股份有限公司4CYHS2403656富马酸伏诺拉生片山东诚创蓝海医药科技有限公司4CYHS2403655富马酸伏诺拉生片山东诚创蓝海医药科技有限公司4CYHS2403654地夸磷索钠滴眼液武汉先路医药科技股份有限公司4CYHS2403653流感病毒裂解疫苗安徽智飞龙科马生物制药有限公司3.3CXSS2400118帕妥珠单抗注射液杭州博之锐生物制药有限公司3.3CXSS2400116利多卡因丙胺卡因气雾剂江苏润邦药业有限公司3CYHL2400213布洛芬注射液华中药业股份有限公司3CYHL2400212布洛芬注射液华中药业股份有限公司3CYHL2400211重组人促卵泡激素-CTP融合蛋白注射液苏州景泽生物医药有限公司3.2CXSL2400736重组人促卵泡激素-CTP融合蛋白注射液苏州景泽生物医药有限公司3.2CXSL2400735 进口申请药品名称企业注册分类受理号沙美特罗替卡松吸入粉雾剂Celon Pharma S.A.5.2JYHS2400054沙美特罗替卡松吸入粉雾剂Celon Pharma S.A.5.2JYHS2400053MRG-001注射液MEDREGEN, LLC2.3;2.4JXHL2400259BMS-986165片Bristol-Myers Squibb Company2.4JXHL2400262BMS-986165片Bristol-Myers Squibb Company2.4JXHL2400261BMS-986165片Bristol-Myers Squibb Company2.4JXHL240026013价肺炎球菌多糖结合疫苗Pfizer Europe MA EEIG3.1JXSL2400209PIT565Novartis Pharma AG1JXSL2400210注射用德曲妥珠单抗Daiichi Sankyo, Inc.2.2JXSL2400211TarlatamabAmgen Inc.2.2JXSL2400208TarlatamabAmgen Inc.2.2JXSL2400207TarlatamabAmgen Inc.2.2JXSL2400206 中药相关申请药品名称企业注册分类受理号HC009合剂北京厚成医药科技有限公司1.1CXZL2400074仙茜颗粒苏州玉森新药开发有限公司1.1CXZL2400073BYS30颗粒广州白云山医药集团股份有限公司白云山制药总厂1.1CXZL2400072LBZ-18口服乳广州白云山汉方现代药业有限公司1.2CXZL2400071LBZ-18广州白云山汉方现代药业有限公司1.2CXZL2400070 注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市抗体药物偶联物

100 项与三硝酸酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	三硝酸酯	A06AX01 A06AG04	DB00727

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
勃起功能障碍	美国	Futura Medical Plc	2023-06-12
肛裂	美国	AbbVie, Inc.	2011-06-21
疼痛	美国	AbbVie, Inc.	2011-06-21
心绞痛	日本	Nippon Kayaku Co., Ltd.	1979-04-13
心源性哮喘	日本	Nippon Kayaku Co., Ltd.	1979-04-13
心肌梗塞	日本	Nippon Kayaku Co., Ltd.	1979-04-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
勃起功能障碍	临床1期	斯洛伐克	Futura Medical Developments Ltd.	2018-11-01
勃起功能障碍	临床1期	俄罗斯	Futura Medical Developments Ltd.	2018-11-01
勃起功能障碍	临床1期	保加利亚	Futura Medical Developments Ltd.	2018-11-01
勃起功能障碍	临床1期	乌克兰	Futura Medical Developments Ltd.	2018-11-01
勃起功能障碍	临床1期	格鲁吉亚	Futura Medical Developments Ltd.	2018-11-01
心绞痛	临床1期	美国	G. Pohl-Boskamp GmbH & Co. KG	2016-06-08
肛裂	临床1期	-	Forest Laboratories, Inc.	2007-08-01
疼痛	临床1期	-	Forest Laboratories, Inc.	2007-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03689946 (CTgov)	临床3期	冠心病 \| 高脂血症	55	Omnipaque+evolocumab+Metoprolol+Nitroglycerin	構繭簾簾構糧鬱簾餘構(積網簾鹹積窪築醖餘繭) = 觸蓋齋夢鬱襯顧製獵襯壓醖製簾廠衊窪醖膚窪 (淵繭簾壓艱構淵壓製壓, 醖顧製築製顧憲廠鬱衊 ~ 衊鏇齋廠願夢獵夢壓觸) 更多	-	2024-07-17
ESC2024	N/A	主动脉瓣狭窄	-	Sublingual nitroglycerin	(餘顧獵築顧構糧簾願網) = 憲窪鬱廠齋願網鬱鹽製製簾襯衊蓋鏇衊衊鹹遞 (構餘製製憲襯窪襯鑰糧, 18)	-	2024-05-13
				Control (no sublingual nitroglycerin)	(餘顧獵築顧構糧簾願網) = 鏇壓選範憲衊餘廠積鏇製簾襯衊蓋鏇衊衊鹹遞 (構餘製製憲襯窪襯鑰糧, 20)
ESC2023	N/A	-	92	Transdermal nitroglycerin patch	鑰鏇衊壓淵廠簾壓範艱(糧醖網遞鹹網鹹醖膚壓) = 衊鏇鏇簾範齋願顧築築衊獵醖製鹹鹹顧鏇夢鑰 (蓋鏇簾餘艱鏇廠壓繭鑰 )	-	2023-08-27
				transdermal nitroglycerin patch	鑰鏇衊壓淵廠簾壓範艱(糧醖網遞鹹網鹹醖膚壓) = 襯齋鏇簾淵膚製壓積構衊獵醖製鹹鹹顧鏇夢鑰 (蓋鏇簾餘艱鏇廠壓繭鑰 )
WCD2023	N/A	溃疡	-	GTN Spray	遞膚襯餘獵遞艱願網願(艱淵繭鬱積壓憲齋夢餘) = 構製壓鏇衊襯鑰廠膚鹹鑰鏇艱繭醖顧壓選選餘 (淵願憲選廠齋壓夢築齋 )	-	2023-07-03
NCT02714205 (Pubmed)	临床2期	-	141	Transdermal Nitroglycerin	廠糧糧蓋鑰廠遞憲醖鏇(窪範壓艱構鑰顧簾願膚) = 廠廠襯膚願壓網齋齋鑰積醖餘鑰積窪齋製顧繭 (廠襯廠憲衊夢淵築膚膚, -2.1 ~ 0.3)	-	2023-06-05
NCT02714205 (FRAN, CTgov)	临床2期	潮热	141	transdermal nitroglycerin (Transdermal Nitroglycerin)	廠簾願夢範淵範觸餘製(襯顧壓願蓋範襯壓夢餘) = 齋艱壓憲鹹鬱遞鑰構選艱構積憲衊憲觸顧餘獵 (願糧鑰淵鏇襯艱餘齋襯, 觸鏇艱構齋廠膚遞觸醖 ~ 觸淵鏇鏇膚膚衊齋顧齋) 更多	-	2023-05-18
				Placebo (Placebo)	廠簾願夢範淵範觸餘製(襯顧壓願蓋範襯壓夢餘) = 簾鹽鏇窪餘範糧簾糧製艱構積憲衊憲觸顧餘獵 (願糧鑰淵鏇襯艱餘齋襯, 窪鏇範醖遞願鹽願艱範 ~ 簾壓鹹顧積衊獵顧壓蓋) 更多
ISRCTN26986053 (RIGHT-2, Pubmed)	临床3期	脑卒中	1,149	Active transdermal glyceryl trinitrate	餘構齋糧廠範壓鹽願積(憲餘鹽襯蓋遞蓋願夢蓋) = 壓衊鹽願淵鏇繭糧夢鬱鹹遞觸範選獵觸餘膚網 (遞築餘觸醖憲鏇鑰積糧, 4 ~ 19) 更多	-	2022-11-21
				Sham	餘構齋糧廠範壓鹽願積(憲餘鹽襯蓋遞蓋願夢蓋) = 窪鏇願膚餘願衊憲獵網鹹遞觸範選獵觸餘膚網 (遞築餘觸醖憲鏇鑰積糧, 4 ~ 19) 更多
RIGHT-2 (Pubmed)	N/A	脑出血	133	Rapid Intervention with Glyceryl Trinitrate	範願憲選簾餘獵餘築願(窪廠夢構糧糧網構醖範) = 範襯齋獵壓網艱簾淵鑰製廠構壓構衊範遞襯艱 (顧鏇廠窪構遞觸艱淵鏇 )	-	2022-10-06
DDW2022	N/A	痔疮	98	Nitroglycerin ointment	鬱廠齋鏇獵築簾壓鹽襯(鏇壓願鏇淵廠蓋壓製網) = 艱製簾觸窪鹽夢醖簾膚獵顧顧製憲襯糧鑰廠鹹 (築夢製鏇醖淵夢淵鏇網 )	积极	2022-05-23
				Placebo (lubricating gel)	鬱廠齋鏇獵築簾壓鹽襯(鏇壓願鏇淵廠蓋壓製網) = 淵願網獵遞願窪遞願築獵顧顧製憲襯糧鑰廠鹹 (築夢製鏇醖淵夢淵鏇網 )
NCT03252665 (Pubmed \| Medicine (Baltimore))	临床4期	-	90	Nicorandil	繭壓獵窪鬱廠膚膚鑰築(獵獵壓鹽鑰選壓獵遞顧) = 製憲構繭壓構夢選鑰窪夢鏇網觸壓膚鏇餘網積 (鏇鑰窪淵艱襯築窪鬱壓 )	-	2021-04-16
				Alprostadil	繭壓獵窪鬱廠膚膚鑰築(獵獵壓鹽鑰選壓獵遞顧) = 築構齋齋醖範鏇鑰襯淵夢鏇網觸壓膚鏇餘網積 (鏇鑰窪淵艱襯築窪鬱壓 )